Trump announces deal with Regeneron Pharmaceuticals, reducing drug prices – One America News Network

OAN Staff Jenna Lee and Brooke Mallory
6:53 PM – Thursday, April 23, 2026

President Donald Trump announced a deal with Regeneron, a drug manufacturer and biotechnology company, to reduce the cost of its pharmaceutical products, marking a key milestone in the administration’s flagship drug-pricing initiative.

Under the terms of the agreement, the president stated that Regeneron will lower prices for its entire portfolio, including future releases, within the Medicaid system. Additionally, as confirmed via a White House Fact Sheet, the deal includes offering the cholesterol medication Praluent for $225 through the TrumpRx discount platform.

“It should be front page news,” Trump said while he announced the deal. “We should win the midterms, but it doesn’t work that way, unfortunately,” Trump added.

 

This deal emerges as the Trump administration prioritizes economic relief ahead of the November midterm elections, addressing the strain that rising costs for healthcare, fuel, and groceries have placed on American households.

Regeneron is the final entry in a group of 17 major pharmaceutical companies to reach an agreement with the administration, following a series of formal letters sent by the president last July demanding that domestic drug prices align with those of other developed nations.

This partnership is particularly notable given President Trump’s personal history with the manufacturer; during his 2020 hospitalization for COVID-19, he received an experimental antibody cocktail from Regeneron and subsequently released a video from the White House lawn praising the treatment’s efficacy.

Additionally, beyond pricing adjustments, the White House confirmed that Regeneron has committed to investing $27 billion in domestic research, development, and manufacturing. Such commitments have typically allowed companies to secure relief from administration tariffs, a hallmark of the president’s “America First” industrial strategy.

The timing of the agreement also coincides with a significant medical breakthrough, as the Food and Drug Administration (FDA) recently approved Regeneron’s gene therapy, Otarmeni. Designed to restore natural hearing in patients with a specific form of congenital deafness, the company celebrated the launch on social media, signaling a new era of 24/7 auditory health.